Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1997 Dec;88(12):1218–1223. doi: 10.1111/j.1349-7006.1997.tb00352.x

Enhanced Topoisomerase I Activity and Increased Topoisomerase IIα Content in Cisplatin‐resistant Cancer Cell Lines

Yukihisa Minagawa 1,✉, Junzo Kigawa 1, Takashi Irie 1, Yasunobu Kanamori 1, Hiroaki Itamochi 1, Xiusi Cheng 1, Naoki Terakawa 1
PMCID: PMC5921345  PMID: 9473741

Abstract

Although the combined effects of cisplatin (CDDP) and DNA topoisomerase (Topo) inhibitors have been described in recent literature, little is known about the combined effects and their biological basis in CDDP‐resistant cells. The aim of the present study was to elucidate the combined effect of CDDP and Topo inhibitors on CDDP‐resistant cells as well as to investigate the biological factors involved in the sensitivity to these anti‐cancer agents. We found synergistic actions between CDDP and SN‐38 (a Topo I inhibitor) or VP‐16 (a Topo II inhibitor) in KFr cells, a CDDP‐resistant subline of the KF epithelial ovarian carcinoma cell line, but not in the parent KF cells. We subsequently assayed Topo protein levels and enzymatic activities in two sets of CDDP‐sensitive and ‐resistant cell lines: KF and KFr, and HeLa and HeLa/CDDP. The levels of Topo I protein in the CDDP‐resistant cells did not differ from those of their parent cell lines and were unaffected by exposure to CDDP. Topo I enzymatic activity, however, was 2‐ to 4‐fold higher in the CDDP‐resistant cell lines than in their respective parent cell lines. In contrast, higher levels of Topo lice protein were observed both before and after CDDP exposure in the CDDP‐resistant cells than in their controls. However, no difference in Topo II catalytic activity was observed between the CDDP‐resistant and ‐sensitive cells.

Keywords: Cisplatin, Drug‐resistance, Topoisomerase I, Topoisomerase II, Cancer cells

Full Text

The Full Text of this article is available as a PDF (357.5 KB).

REFERENCES

  • 1. ) Loehrer , P. J. and Einhorn , L. H.Drugs five years later. Cisplatin . Ann. Intern. Med. , 100 , 704 – 713 ( 1984. ). [DOI] [PubMed] [Google Scholar]
  • 2. ) Ozols , R. F. and Young , R. C.Chemotherapy of ovarian cancer . Sem. Oncol. , 11 , 251 – 263 ( 1984. ). [PubMed] [Google Scholar]
  • 3. ) Scanlon , K. J. , Kashani‐Sabet , M. , Miyachi , H. , Sowers , L. C. and Rossi , J.Molecular basis of cisplatin resistance in human carcinomas; model systems and patients . Anticancer Res. , 9 , 1301 – 1312 ( 1989. ). [PubMed] [Google Scholar]
  • 4. ) Andrews , P. A. and Howell , S. B.Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance . Cancer Cells , 2 , 35 – 43 ( 1990. ). [PubMed] [Google Scholar]
  • 5. ) Drlica , K. and Franco , R. J.Inhibitors of DNA topoiso‐merases . Biochemistry , 27 , 2253 – 2259 ( 1988. ). [DOI] [PubMed] [Google Scholar]
  • 6. ) Cain , J. M. , Collins , C. , Petersdorf , S. , Figge , D. C. , Tamimi , H. K. , Greer , B. E. and Livingston , R. B.Phase II study of high‐dose cisplatin, etoposide, and cyclophosphamide for refractory ovarian cancer . Am. J.Obstet. Gynecol. , 174 , 1688 – 1694 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 7. ) Zanaboni , F. , Scarfone , G. , Presti , M. , Maggi , R. , Borello , C. and Bolis , G.Salvage chemotherapy for ovarian cancer recurrence: weekly cisplatin in combination with epirubicin or etoposide . Gynecol. Oncol. , 43 , 24 – 28 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 8. ) Fujiwara , Y. , Sugimoto , Y. , Kasahara , K. , Bungo , M. , Yamakido , M. , Tew , K. D. and Saijo , N.Determinants of drug response in a cisplatin‐resistant human lung cancer cell line . Jpn. J. Cancer Res. , 81 , 527 – 535 ( 1990. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. ) Hertzberg , R. P. , Caranfa , M. J. and Hecht , S. M.On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme‐DNA complex . Biochemistry , 28 , 4629 – 4638 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 10. ) Kunimoto , T. , Nitta , K. , Tanaka , T. , Uehara , N. , Baba , H. , Takeuchi , M. , Yokokura , T. , Sawada , S. , Miyasaka , T. and Mutai , M.Antitumor activity of 7‐ethyl‐10‐[4‐(l‐piperidino)‐l‐ piperidino]carbonyloxycamptothecin, a novel water‐soluble derivative of camptothecin, against murine tumors . Cancer Res. , 47 , 5944 – 5947 ( 1987. ). [PubMed] [Google Scholar]
  • 11. ) Masuda , N. , Fukuoka , M. , Takada , M. , Kusunoki , Y. , Negoro , S. , Matsui , K. , Kudoh , S. , Takifuji , N. , Nakagawa , K. and Kishimoto , S.CPT‐11 in combination with cisplatin for advanced non‐small‐cell lung cancer . J Clin. Oncol. , 10 , 1775 – 1780 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 12. ) Minagawa , Y. , Kigawa , J. , Ishihara , H. , Itamochi , H. and Terakawa , N.Synergistic enhancement of cisplatin cyto‐toxicity by SN‐38, an active metabolite of CPT‐11, for cisplatin‐resistant HeLa cells . Jpn. J. Cancer Res. , 85 , 966 – 971 ( 1994. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. ) Kikuchi , Y. , Miyauchi , M. , Kizawa , I. , Oomori , K. and Kato , K.Establishment of cisplatin‐resistant human ovarian cancer cell line . J Natl. Cancer Inst. , 77 , 1181 – 1185 ( 1986. ). [PubMed] [Google Scholar]
  • 14. ) Mosmann , T.Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays . J Immunol. Methods , 65 , 55 – 63 ( 1983. ). [DOI] [PubMed] [Google Scholar]
  • 15. ) Kano , Y. , Suzuki , K. , Akutsu , M. , Suda , K. , Inoue , Y. , Yoshida , M. , Sakamoto , S. and Miura , Y.Effects of CPT‐11 in combination with other anti‐cancer agents in culture . Int. J. Cancer , 50 , 604 – 610 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 16. ) Bradford , M. M.A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein‐dye binding . Anal. Biochem. , 72 , 248 – 254 ( 1976. ). [DOI] [PubMed] [Google Scholar]
  • 17. ) Laemmli , U. K.Cleavage of structural proteins during the assembly of the head of bacteriophage T4 . Nature , 227 , 680 – 685 ( 1970. ). [DOI] [PubMed] [Google Scholar]
  • 18. ) Crespi , M. D. , Ivanier , S. E. , Genovese , J. and Baldi , A.Mitoxantrone affects topoisomerase activities in human breast cancer cells . Biochem. Biophys. Res. Commun. , 136 , 521 – 528 ( 1986. ). [DOI] [PubMed] [Google Scholar]
  • 19. ) Liu , L. F. and Miller , K. G.Eukaryotic DNA topoisomer‐ases: two forms of type I DNA topoisomerases from HeLa nuclei . Proc. Natl. Acad. Sci. USA , 78 , 3487 – 3491 ( 1981. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. ) Marini , J. C. , Miller , K. G. and Englund , P. T.Decatenationof kinetoplastDNA bytopoisomerases . J. Biol Chem. , 255 , 4976 – 4979 ( 1980. ). [PubMed] [Google Scholar]
  • 21. ) Miller , K. G. , Liu , L. F. and Englund , P. T.A homogeneous type II DNA topoisomerase from HeLa cell nuclei . J. Biol. Chem. , 256 , 9334 – 9339 ( 1981. ). [PubMed] [Google Scholar]
  • 22. ) Kotoh , S. , Naito , S. , Yokomizo , A. , Kumazawa , J. , Asakuno , K. , Kohno , K. and Kuwano , M.Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin‐resistant bladder cancer cells . Cancer Res. , 54 , 3248 – 3252 ( 1994. ). [PubMed] [Google Scholar]
  • 23. ) Fukuda , M. , Nishio , K. , Kanazawa , F. , Ogasawara , H. , Ishida , T. , Arioka , H. , Bojanowski , K. , Oka , M. and Saijo , N.Synergism between cisplatin and topoisomerase I inhibitors, NB‐506 and SN‐38, in human small cell lung cancer cells . Cancer Res. , 56 , 789 – 793 ( 1996. ). [PubMed] [Google Scholar]
  • 24. ) van der Zee , A. G. J. , de Jong , S. , Keith , W. N. , Hollema , H. , Boonstra , H. and de Vries , E. G. E.Quantitative and qualitative aspects of topoisomerase I and IIα and β in untreated and platinum/cyclophosphamide treated malignant ovarian tumors . Cancer Res. , 54 , 749 – 755 ( 1994. ). [PubMed] [Google Scholar]
  • 25. ) de Jong , S. , Timmer‐Bosscha , H. , de Vries , E. G. E. and Mulder , N. H.Effect of novobiocin on cisplatin cytotoxicity and DNA interstrand cross‐link formation in a cisplatin‐resistant, small‐cell lung carcinoma cell line . Int. J, Cancer , 53 , 110 – 117 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 26. ) Mamenta , E. L. , Poma , E. E. , Kaufmann , W. K. , Delmastro , D. A. , Grady , H. L. and Chaney , S. G.Enhanced replicative bypass of platinum‐DNA adducts in cisplatin‐resistant human ovarian carcinoma cell lines . Cancer Res. , 54 , 3500 – 3505 ( 1994. ). [PubMed] [Google Scholar]
  • 27. ) Barret , J. M. , Calsou , P. , Larsen , A. K. and Salles , B.A cisplatin‐resistant murine leukemia cell line exhibits increased topoisomerase II activity . Mol. Pharmacol. , 46 , 431 – 436 ( 1994. ). [PubMed] [Google Scholar]
  • 28. ) Brown , G. A. , McPherson , J. P. , Gu , L. , Hedley , D. W. , Toso , R. , Deuchars , K. L. , Freedman , M. H. and Goldenberg , G. J.Relationship of DNA topoisomerase IIαand β expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines . Cancer Res. , 55 , 78 – 82 ( 1995. ). [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES